- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Bacterial toxins.
Displaying page 1 of 1.
| EudraCT Number: 2019-002225-30 | Sponsor Protocol Number: 69HCL18_0957 | Start Date*: 2019-07-18 | ||||||||||||||||
| Sponsor Name:Hospices Civils de Lyon | ||||||||||||||||||
| Full Title: Impact of low protein diet supplemented with ketoanalogues on uremic toxins production and glucose metabolism in chronic kidney disease_KETO GUT study | ||||||||||||||||||
| Medical condition: chronic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2011-006094-26 | Sponsor Protocol Number: CTP_STX005/STX005EXT | Start Date*: 2012-02-10 | |||||||||||
| Sponsor Name:Thallion Pharmaceuticals Inc | |||||||||||||
| Full Title: A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (caStx1) and 2 (caStx2) Administered Concomitantly to Children with Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody ... | |||||||||||||
| Medical condition: Prevention of Shiga toxin-mediated complications resulting from Shiga toxin producing bacterial infections. | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-003444-80 | Sponsor Protocol Number: 2020-01471 | Start Date*: 2020-11-17 |
| Sponsor Name:Sahlgrenska University Hospital | ||
| Full Title: Evaluation of the clinical implementation of biofilm susceptibility to antibiotics using Minimum Biofilm Eradication Concentration (MBEC) in addition to Minimum Inhibitory Concentration (MIC) to gu... | ||
| Medical condition: Periprosthetic hip or knee joint infections | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-010191-19 | Sponsor Protocol Number: ALS-002-2009 | Start Date*: 2010-03-19 | |||||||||||
| Sponsor Name:Alloksys Life Sciences BV | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled phase IIIa study on bIAP, an anti-inflammatory moiety, in patients undergoing combined aortic valve replacement and coronary artery bypass grafting. | |||||||||||||
| Medical condition: Patients undergoing invasive cardiac surgery with prolonged perfusion time. This often is associated with potentially life-threatening inflammatory complications due to ischemic periods during surg... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-000775-32 | Sponsor Protocol Number: H-030-014 | Start Date*: 2013-08-13 | |||||||||||||||||||||||||||||||
| Sponsor Name:Sanofi Pasteur Inc | |||||||||||||||||||||||||||||||||
| Full Title: Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection | |||||||||||||||||||||||||||||||||
| Medical condition: Prevention of primary Clostridium difficile infection | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: FI (Completed) SE (Completed) GB (Completed) DE (Completed) ES (Completed) DK (Completed) PL (Completed) CZ (Completed) RO (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2018-000102-33 | Sponsor Protocol Number: 69HCL16_0079 | Start Date*: 2018-03-22 | |||||||||||
| Sponsor Name:Hospices Civils de Lyon | |||||||||||||
| Full Title: Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in children: a multicenter European randomized controlled trial | |||||||||||||
| Medical condition: toxic shock syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Not Authorised) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-001822-81 | Sponsor Protocol Number: TJT1106 | Start Date*: 2011-09-06 | ||||||||||||||||
| Sponsor Name:CHU-Ulg | ||||||||||||||||||
| Full Title: Infusion of third-party mesenchymal stem cells after renal or liver transplantation: a phase I-II, open-label, clinical study. | ||||||||||||||||||
| Medical condition: Liver failure: end-stage liver diseases, including cirrhosis, primary liver cancer, fulminant hepatic failure and numerous other metabolic or congenital hepatic diseases. Kidney failure: end-st... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2021-006883-25 | Sponsor Protocol Number: AR-AB-AD | Start Date*: 2022-07-06 | ||||||||||||||||
| Sponsor Name:Bispebjerg hospital, Dermato-Venerologisk afdeling, Jacob Pontoppidan Thyssen | ||||||||||||||||||
| Full Title: The Pathogenic Role Of Staphylococcus Aureus And The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis | ||||||||||||||||||
| Medical condition: Atopic dermatitis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2011-004590-90 | Sponsor Protocol Number: 3415A-001 | Start Date*: 2012-02-17 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium ... | |||||||||||||
| Medical condition: recurrence of Clostridium difficile infection (CDI) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) CZ (Completed) BE (Completed) DK (Completed) PT (Completed) AT (Completed) IT (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.